参考文献/References:
[1] Jia W.Obesity in China: its characteristics, diagnostic criteria, and implications[J].Front Med,2015,9(2):129-133.DOI:10.1007/s11684-015-0387-x.
[2] Kriz W,Lemley KV.A potential role for mechanical forces in the detachment of podocytes and the progression of CKD[J].J Am Soc Nephrol,2015,26(2):258-269.DOI:10.1681/ASN.2014030278.
[3] Wuerzner G,Pruijm M,Maillard M,et al.Marked association between obesity and glomerular hyperfiltration: a cross-sectional study in an African population[J].Am J Kidney Dis,2010,56(2):303-312.DOI:10.1053/j.ajkd.2010.03.017.
[4] Praga M,Morales E.The fatty kidney: obesity and renal disease[J].Nephron,2017,136(4):273-276.DOI:10.1159/000447674.
[5] Nolan E,O'Meara YM,Godson C. Lipid mediators of inflammation in obesity-related glomerulopathy[J].Nephrol Dial Transplant,2013,28(Suppl 4):iv22-iv29.DOI:10.1093/ndt/gft392.
[6] 高原.肿瘤坏死因子α、白细胞介素6与IgA肾病足细胞损伤的相关研究[D].河北医科大学,2017.
[7] Nasrallah MP,Ziyadeh FN.Overview of the physiology and pathophysiology of leptin with special emphasis on its role in the kidney[J].Semin Nephrol,2013,33(1):54-65.DOI:10.1016/j.semnephrol.2012.12.005.
[8] Hatunic M,Finucane F,Burns N,et al.Vascular inflammatory markers in early-onset obese and type 2 diabetes subjects before and after three months' aerobic exercise training[J].Diab Vasc Dis Res,2007,4(3):231-234.DOI:10.3132/dvdr.2007.045.
[9] Real JT,Folgado J,Molina Mendez M,et al.Plasma homocysteine, Lp(a), and oxidative stress markers in peripheral macroangiopathy in patients with type 2 diabetes mellitus[J].Clin Investig Arterioscler,2016,28(4):188-194.DOI:10.1016/j.arteri.2016.05.007.
[10] Maul B,Becker M,Gembardt F,et al.Genetic deficiency in neprilysin or its pharmacological inhibition initiate excessive stress-induced alcohol consumption in mice[J].PLoS One,2012,7(11):e50187.DOI:10.1371/journal.pone.0050187.
[11] Coward RJ,Welsh GI,Yang J,et al.The human glomerular podocyte is a novel target for insulin action[J].Diabetes,2005,54(11):3095-3102.
[12] De Cosmo S,Menzaghi C,Prudente S,et al.Role of insulin resistance in kidney dysfunction: insights into the mechanism and epidemiological evidence[J].Nephrol Dial Transplant,2013,28(1):29-36.DOI:10.1093/ndt/gfs290.
[13] Muscogiuri G,Cignarelli A,Giorgino F,et al.GLP-1: benefits beyond pancreas[J].J Endocrinol Invest,2014,37(12):1143-1153.DOI:10.1007/s40618-014-0137-y.
[14] Gutzwiller JP,Tschopp S,Bock A,et al.Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men[J].J Clin Endocrinol Metab,2004,89(6):3055-3061.DOI:10.1210/jc.2003-031403.
[15] Marso SP,Daniels GH,Brown-Frandsen K,et al.Liraglutide and cardiovascular outcomes in type 2 diabetes[J].N Engl J Med,2016,375(4):311-322.DOI:10.1056/NEJMoa1603827.
[16] Skov J,Pedersen M,Holst JJ,et al.Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial[J].Diabetes Obes Metab,2016,18(6):581-589.DOI:10.1111/dom.12651.
[17] Raun K,von Voss P,Gotfredsen CF,et al.Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-Ⅳ inhibitor, vildagliptin, does not[J].Diabetes,2007,56(1):8-15.DOI:10.2337/db06-0565.
[18] Guo H,Wang B,Li H,et al.Glucagon-like peptide-1 analog prevents obesity-related glomerulopathy by inhibiting excessive autophagy in podocytes[J].Am J Physiol Renal Physiol,2018,314(2):F181-F189.DOI:10.1152/ajprenal.00302.2017.
[19] Wang C,Li L,Liu S,et al.GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis[J].PLoS One,2018,13(3):e0193473.DOI:10.1371/journal.pone.0193473.
[20] Glastras SJ,Chen H,McGrath RT,et al.Effect of GLP-1 receptor activation on offspring kidney health in a rat model of maternal obesity[J].Sci Rep,2016,6:23525. DOI:10.1038/srep23525.
[21] Zavattaro M,Caputo M,Samà MT,et al.One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study[J].Endocrine,2015,50(3):620-626.DOI:10.1007/s12020-014-0519-0.
[22] Guebre-Egziabher F,Alix PM,Koppe L,et al.Ectopic lipid accumulation: a potential cause for metabolic disturbances and a contributor to the alteration of kidney function[J].Biochimie,2013,95(11):1971-1979.DOI:10.1016/j.biochi.2013.07.017.
[23] 吴晓静.高脂喂养大鼠肾脏NF-κB及炎症因子表达变化及利拉鲁肽的干预研究[D].承德医学院,2017.
[24] Fujita H,Morii T,Fujishima H,et al.The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential[J].Kidney Int,2014,85(3):579-589.DOI:10.1038/ki.2013.427.
[25] Dai Y, Mehta JL, Chen M. Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cellby repressing nuclear factor-kappa B activation[J].Cardiovasc Drugs Ther,2013,27(5):371-380. DOI:10.1007/s10557-013-6463-z.
[26] Shiraki A,Oyama J,Komoda H,et al.The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells[J].Atherosclerosis,2012,221(2):375-382.DOI: 10.1016/j.atherosclerosis.2011.12.039.
[27] Ishibashi Y,Matsui T,Ojima A,et al.Glucagon-like peptide-1 inhibits angiotensin Ⅱ-induced mesangial cell damage via protein kinase A[J].Microvasc Res,2012,84(3):395-398.DOI:10.1016/j.mvr.2012.06.008.
[28] Hendarto H,Inoguchi T,Maeda Y,et al.GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases[J].Metabolism,2012,61(10):1422-1434.DOI:10.1016/j.metabol.2012.03.002.
[29] 索琳娜,王薇.利拉鲁肽对高脂饮食诱导的肥胖大鼠血清网膜素1及胰岛素抵抗的影响[J].中国医科大学学报,2015,44(12):1129-1131.DOI:10.3969/j.issn.0258-4646.2015.12.018.
[30] Nicolucci A,Rossi MC.Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes[J].Acta Biomed,2008,79(3):184-191.
[31] Madsbad S.The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications[J].Diabetes Obes Metab,2014,16(1):9-21.DOI:10.1111/dom.12119.
相似文献/References:
[1]田甜,沈山梅.肠促胰素与骨质疏松[J].国际内分泌代谢杂志,2016,36(05):320.[doi:10.3760/cma.j.issn.1673-4157.2016.05.09]
Tian Tian,Shen Shanmei.Incretin and osteoporosis[J].International Journal of Endocrinology and Metabolism,2016,36(01):320.[doi:10.3760/cma.j.issn.1673-4157.2016.05.09]
[2]刘海逸,张欣荣,岳晓丹,等.黄连解毒汤对糖耐量减低大鼠的糖尿病
延缓作用[J].国际内分泌代谢杂志,2017,37(03):149.[doi:10.3760/cma.j.issn.1673-4157.2017.03.002]
Liu Haiyi*,Zhang Xinrong,Yue Xiaodan,et al.Effects of huang-lian-jie-du-decoction in delaying diabetes in rats with impaired glucose tolerance[J].International Journal of Endocrinology and Metabolism,2017,37(01):149.[doi:10.3760/cma.j.issn.1673-4157.2017.03.002]
[3]杨梦萦 袁莉.胰岛内源性胰高血糖素样肽-1信号的研究进展[J].国际内分泌代谢杂志,2019,39(06):413.[doi:10.3760/cma.j.issn.1673-4157.2019.06.013]
Yang Mengying,Yuan Li.Recent progress of the islet endogenous glucagon-like peptide-1 signaling[J].International Journal of Endocrinology and Metabolism,2019,39(01):413.[doi:10.3760/cma.j.issn.1673-4157.2019.06.013]
[4]李钰 孟怡媚 刘宽芝.胰高血糖素样肽-1类似物改善肌肉萎缩的研究进展[J].国际内分泌代谢杂志,2022,42(01):41.[doi:10.3760/cma.j.cn121383-20201026-10032]
Li Yu,Meng Yimei,Liu Kuanzhi..Research progress of glucagon-like peptide-1 analogues in ameliorating muscular atrophy[J].International Journal of Endocrinology and Metabolism,2022,42(01):41.[doi:10.3760/cma.j.cn121383-20201026-10032]